Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

serious adverse events in doses up to 3000 mg.

R7128 demonstrated potent, dose-dependent antiviral activity across four prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration wi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... WOODBRIDGE, ON , June 1, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... to deliver on its business strategies despite its ...
(Date:6/1/2015)... , June 1, 2015  Merrimack Pharmaceuticals, Inc. (Nasdaq: ... injection), also known as ,nal-IRI, in a Phase 1 ... for high-grade glioma. Data were presented at the 2015 ... Chicago, IL. Results from this ... patients with high-grade glioma when given intravenously.  ...
(Date:6/1/2015)... 1, 2015 Select Medical Holdings Corporation (NYSE: ... a joint venture that Select Medical Corporation ("Select") formed ... its previously announced acquisition of Concentra Inc.  Cressey & ... About Select Medical Corporation ... and outpatient rehabilitation clinics in the United ...
Breaking Medicine Technology:Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... Feb. 8, 2012 Mesa Laboratories, Inc. (NASDAQ: MLAB ) ... increase in GAAP net income for the fiscal third quarter ended December ... net income increased 58% year over year to $1,987 ,000 ... Achieved 13% organic year over year sales growth in the fiscal ...
... Feb. 8, 2012 ChemoCentryx, Inc. (NASDAQ: CCXI) announced ... 4,500,000 shares of its common stock at $10.00 per ... common stock is being offered by ChemoCentryx. In addition, ... to an additional 675,000 shares of common stock from ...
Cached Medicine Technology:Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 2Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 3Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 4Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 5ChemoCentryx Announces Pricing of Initial Public Offering 2
(Date:6/2/2015)... North Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... American publisher of audit, compliance and risk ... of a new online risk management effectiveness gap-improvement ... reduce the effect of uncertainty on objectives. Organizations ... but they improve their capabilities to do this ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Miriam Wirski as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this prestigious honor,” said NAPW President Star Jones. ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Woman of the Year ... leadership in life coaching. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Her work as a ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Professional Woman of the ... for leadership in safety, environment, health and emergency response. ... professional women, boasting more than 700,000 members and over ... Lourinda with this important honor,” said NAPW President Star ...
(Date:6/1/2015)... The National Association of Professional ... inductee into its VIP Woman of the Year ... for leadership in business. NAPW is the nation’s ... more than 700,000 members and over 200 operating ... into this exceptional group of professional women,” said ...
Breaking Medicine News(10 mins):Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2
... prevalence of hay fever and eczema in the U.K has ... ,In the research that has been published today published ... Edinburgh have said that the rates of eczema and hay ... rise but at the same time allergic reactions to food ...
... risk of developing lymphoma and leukemia. The autoimmune, inflammatory ... have the risk of cancer. //Researchers speculate that antirheumatic ... antagonists, a type of biologic DMARD may play a ... by attaching to and impeding chemical messengers behind inflammation, ...
... Asian children must be given Vitamin D supplements from birth ... reappearance of deficiency symptoms. //Researchers examined the present of vitamin ... findings in the latest issue of Archives of Disease in ... tooth formation, convulsions, general ill health, and stunted growth. And ...
... cards no longer have the last say concerning the removal ... come into force that will make the deceased person’s wishes ... card, their relatives can prevent doctors from harvesting their organs. ... so. ,The new laws have come into place as part ...
... decrease in traumatic head injuries among Canadians under age ... report released on Wednesday.// ,When the Canadian Institute ... head injuries from 1994 to 2004 it found that ... 1994, with children and youth showing the largest drop. ...
... that humans are genetically more suited to being vegetarians than ... Queenstown// conference by more then 300 leading scientists from New ... and finding a cure for cancer is also under discussion ... the Convener of the conference says the finding that a ...
Cached Medicine News:Health News:Eczema And Hay Fever Decline In UK While Allergic Reactions On The Rise 2Health News:RA Drugs Not Implicated In Cancer 2Health News:Asian Children Need More Vitamin D Supplements 2Health News:Families of the Dead no Longer Have the Last Say 2Health News:Families of the Dead no Longer Have the Last Say 3
... It's easy on delicate ... design and hydrophilic coating provide ... lubricating gel. It's easy to ... the catheter with its own ...
... delicate urethral tissues. The gentle, ... provide nearly friction-free movement, without ... to maintain sterility. You simply ... own sterile water, avoiding contamination ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: